bibliographicCitation |
Jiang Y, Li C, Ma Y, Chen J, Li Y, Chen L. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines. Clin Lab. 2012;58(5-6):551–61. PMID: 22783588. |